Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Triptorelin (Decapeptyl® SR) is recommended as an option for use within NHS Wales as an adjuvant treatment to radiotherapy in patients with high risk localised or locally advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. |
|||
|
|||
Medicine details |
|||
| Medicine name | triptorelin (Decapeptyl® SR) | ||
| Formulation | 22.5 mg powder and solvent for suspension for injection, 11.25 mg powder for suspension for injection, 3 mg powder for suspension for injection | ||
| Reference number | 1658 | ||
| Indication | Adjuvant treatment to radiotherapy in patients with high risk localised or locally advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer |
||
| Company | Ipsen Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0417 | ||
| NMG meeting date | 11/01/2017 | ||
| AWMSG meeting date | 15/02/2017 | ||
| Date of issue | 14/03/2017 | ||
| Date of last review | September 2020 | ||